This statistic shows the death rate from liver cirrhosis in the U.S. in 2019, by age. According to the data, during that time the highest death rate was 37.9 per 100,000 and was among those aged 75-84 years.

In 2023, the death rate due to alcohol-related liver cirrhosis among those aged 45-54 years was 11.9 per 100,000. This statistic shows the rate of alcohol-related liver cirrhosis deaths in the U.S. in 2023, by age.

Legacy unique identifier: P00204

This dataset present information on the age-standardized prevalence of liver cirrhosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

This dataset present information on the age-sex specific incidence rate of liver cirrhosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

This dataset present information on the age-standardized incidence rate of liver cirrhosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

This statistic displays the number of alcoholic liver disease related deaths in England in 2021, by gender and age. The number of deaths from alcoholic liver disease was significantly higher among men than women. In 2021, 678 men and 401 women aged between 55 and 59 years old died from alcoholic liver disease.

This dataset present information on the age-standardized prevalence of liver cirrhosis for Alberta Health Service (AHS) and five AHS Continuum zones expressed as per 100,000 population and as a percentage.

BackgroundLiver cirrhosis mortality number has increased over the last decades. We aimed to estimate the liver cirrhosis mortality rate and its trends for the first time by sex, age, geographical distribution, and cause in Iran.MethodIranian Death Registration System, along with demographic (Complete and Summary Birth History, Maternal Age Cohort and Period methods) and statistical methods (Spatio-temporal and Gaussian process regression models) were used to address the incompleteness and misclassification and uncertainty of death registration system to estimate annual cirrhosis mortality rate. Percentages of deaths were proportionally redistributed into cirrhosis due to hepatitis B, C and alcohol use based on the data from the Global Burden of Disease (GBD) 2010 study.ResultsLiver cirrhosis mortality in elder patients was 12 times higher than that in younger patients at national level in 2015. Over the 26 years, liver cirrhosis mortality in males has increased more than that in females. Plus, the percentage of change in age adjusted mortality rate at provincial levels varied between decreases of 64.53% to nearly 17% increase. Mortality rate has increased until 2002 and then decreased until 2015.The province with highest mortality rate in 2015 has nearly two times greater rate compare to the lowest. More than 60% of liver cirrhosis mortality cases at national level are caused by hepatitis B and C infection. The rate of hepatitis B mortality is four times more than that from hepatitis C.ConclusionThis study demonstrated an increasing and then decreasing pattern in cirrhosis mortality that could be due to national vaccination of hepatitis B program. However monitoring, early detection and treatment of risk factors of cirrhosis, mainly in high risk age groups and regions are essential. Cirrhosis mortality could be diminished by using new non-invasive methods of cirrhosis screening, hepatitis B vaccination, definite treatment of hepatitis C.

This statistic shows the number of liver cirrhosis deaths in the U.S. in 2019, by age. According to the data, among those aged 55 to 64 years, ****** deaths occurred due to liver cirrhosis in 2019.

Liver cirrhosis is a significant yet largely preventable and underappreciated cause of global health loss. This study aimed to profile the global and regional burdens of liver cirrhosis between 2010 and 2019 and the contributions of various aetiologies. Data on the incidence, mortality, and disability-adjusted life years (DALYs) of cirrhosis were obtained from the Global Burden of Disease 2019 study. The burden of cirrhosis was estimated by age, sex, region, aetiology, and socio-demographic index (SDI). The temporal trend was quantified using the annual percentage changes (APC.) Globally, there were 2.05 million new cases and 1.47 million deaths due to cirrhosis in 2019. From 2010 to 2019, the age-standardized incidence rate (ASIR) for cirrhosis increased slightly from 25.19 to 25.35 worldwide, while the age-standardized death rate (ASDR) and age-standardized DALYs (ASDALYs) decreased from 20.37 to 18.00 and 639.86 to 560.43, respectively. Cirrhosis incidence, mortality and DALYs were consistently higher in males than females. Stratification according to the socio-demographic index (SDI) revealed that low SDI countries had the highest ASDR and ASDALYs in 2019, while middle SDI countries had the highest ASIR. Regarding the aetiology of cirrhosis, hepatitis C accounted for the largest proportion of cirrhosis-related incidence (26.9%), death (26.8%) and DALYs (26.3%); however, non-alcoholic fatty liver disease (NAFLD) exhibited a rapidly growing cause of incident cirrhosis (+26.7%), cirrhosis-related death (+25.1%), and DALYs (+21.0%) worldwide during this period. The ASIR for NAFLD also significantly increased with APC 1.080 over the study period. Albeit the global burden of cirrhosis incidence increased from 2010 to 2019, cirrhosis-associated deaths and DALYs declined significantly. Notably, NAFLD exhibited the most significant increase as a contributor to cirrhosis worldwide. Global burden of cirrhosis incidence increased from 2010 to 2019.Cirrhosis-associated death and DALYs declined significantly during this period.Non-alcoholic fatty liver disease (NAFLD) exhibited the most significant increase as a contributor to cirrhosis worldwide. Global burden of cirrhosis incidence increased from 2010 to 2019. Cirrhosis-associated death and DALYs declined significantly during this period. Non-alcoholic fatty liver disease (NAFLD) exhibited the most significant increase as a contributor to cirrhosis worldwide.

Context:

Cirrhosis results from prolonged liver damage, leading to extensive scarring, often due to conditions like hepatitis or chronic alcohol consumption. The data provided is sourced from a Mayo Clinic study on primary biliary cirrhosis (PBC) of the liver carried out from 1974 to 1984.

I have manually cleaned the dataset and used synthetic data to increase samples.

Attribute Information:

• N_Days: Number of days between registration and the earlier of death, transplantation, or study analysis time in 1986
• Status: status of the patient C (censored), CL (censored due to liver tx), or D (death)
• Drug: type of drug D-penicillamine or placebo
• Age: age in days
• Sex: M (male) or F (female)
• Ascites: presence of ascites N (No) or Y (Yes)
• Hepatomegaly: presence of hepatomegaly N (No) or Y (Yes)
• Spiders: presence of spiders N (No) or Y (Yes)
• Edema: presence of edema N (no edema and no diuretic therapy for edema), S (edema present without diuretics, or edema resolved by diuretics), or Y (edema despite diuretic therapy)
• Bilirubin: serum bilirubin in [mg/dl]
• Cholesterol: serum cholesterol in [mg/dl]
• Albumin: albumin in [gm/dl]
• Copper: urine copper in [ug/day]
• Alk_Phos: alkaline phosphatase in [U/liter]
• SGOT: SGOT in [U/ml]
• Tryglicerides: triglicerides in [mg/dl]
• Platelets: platelets per cubic [ml/1000]
• Prothrombin: prothrombin time in seconds [s]
• Stage: histologic stage of disease ( 1, 2, or 3 )

Citation:

Dickson,E., Grambsch,P., Fleming,T., Fisher,L., and Langworthy,A.. (2023). Cirrhosis Patient Survival Prediction. UCI Machine Learning Repository. https://doi.org/10.24432/C5R02G.

This data shows premature deaths (Age under 75) from Liver Disease, numbers and rates by gender, as 3-year moving-averages.

Most liver disease is preventable and much is influenced by alcohol consumption and obesity prevalence, which are both amenable to public health interventions.

Directly Age-Standardised Rates (DASR) are shown in the data (where numbers are sufficient) so that death rates can be directly compared between areas. The DASR calculation applies Age-specific rates to a Standard (European) population to cancel out possible effects on crude rates due to different age structures among populations, thus enabling direct comparisons of rates.

A limitation on using mortalities as a proxy for prevalence of health conditions is that mortalities may give an incomplete view of health conditions in an area, as ill-health might not lead to premature death.

Data source: Public Health England, Public Health Outcomes Framework (PHOF) indicator 4.06i. The data is updated annually.

In 2023, the age-specific mortality rate of chronic liver disease and cirrhosis at all ages in Canada decreased by *** deaths (***** percent) compared to 2022. Nevertheless, the last two years recorded a significantly higher age-specific mortality rate than the preceding years.

BackgroundLiver cirrhosis-related death is a serious threat worldwide. The number of studies exploring the mortality trend of cirrhosis caused by specific etiologies was limited. This study aimed to demonstrate the pattern and trend based on the data of global burden of disease (GBD).MethodsThe data of cirrhosis mortality were collected from the GBD 2017. The Age standardized mortality rate (ASR) and estimated annual percentage changes (EAPC) were used to estimate the temporal trend of liver cirrhosis mortality by etiologies, regions, sociodemographic index (SDI), and sexes.ResultsGlobally, mortality cases of cirrhosis increased by 47.15%. Although the global ASR of cirrhosis mortality remained stable during this period, the temporal trend varied in etiologies. The ASR of mortality caused by hepatitis C virus (HCV), alcohol consumption, and non-alcoholic steatohepatitis (NASH) increased with an EAPC of 0.17 (95% CI, 0.14–0.20), 0.20 (95% CI, 0.16–0.24), 1.00 (95% CI, 0.97–1.04), respectively. A decreasing trend of ASR was found among the causes of hepatitis B virus (BV) and other causes. The increased pattern was heterogeneous worldwide. The most pronounced increase trend was found in middle-high SDI regions and Eastern Europe. Contrarily, the most pronounced decrease trend was found in low SDI regions and Western Sub-Saharan Africa.ConclusionCirrhosis is still a public health problem. The growth trend of cirrhosis mortality caused by HCV was slowed by promoting direct-acting antiviral therapy. Unfortunately, we observed an unfavorable trend in etiologies for alcohol consumption and NASH, which indicated that more targeted and specific strategies should be established to limit alcohol consumption and promote healthy lifestyles in high-risk countries, especially in middle-high SDI regions and Eastern Europe.

In 2019, the global death rate from liver cirrhosis and other chronic liver diseases was over twice as high in men compared to women. Men reported over 24 deaths per 100,000 population, while women reported 11.7 deaths per 100,000 population. This statistic displays the age-standardized death rate (ASR) of liver cirrhosis and other chronic liver diseases worldwide in 2019, by gender.

BackgroundLiver cirrhosis is a major global health and economic challenge, placing a heavy economic burden on patients, families, and society. This study aimed to investigate medical expenditure trends in patients with liver cirrhosis and assess the drivers for such medical expenditure among patients with liver cirrhosis.MethodsMedical expenditure data concerning patients with liver cirrhosis was collected in six tertiary hospitals in Chongqing, China, from 2012 to 2020. Trends in medical expenses over time and trends according to subgroups were described, and medical expenditure compositions were analyzed. A multiple linear regression model was constructed to evaluate the factors influencing medical expenditure. All expenditure data were reported in Chinese Yuan (CNY), based on the 2020 value, and adjusted using the year-specific health care consumer price index for Chongqing.ResultsMedical expenditure for 7,095 patients was assessed. The average medical expenditure per patient was 16,177 CNY. An upward trend in medical expenditure was observed in almost all patient subgroups. Drug expenses were the largest contributor to medical expenditure in 2020. A multiple linear regression model showed that insurance type, sex, age at diagnosis, marital status, length of stay, smoking status, drinking status, number of complications, autoimmune liver disease, and the age-adjusted Charlson comorbidity index score were significantly related to medical expenditure.ConclusionConservative estimates suggest that the medical expenditure of patients with liver cirrhosis increased significantly from 2012 to 2020. Therefore, it is necessary to formulate targeted measures to reduce the personal burden on patients with liver cirrhosis.

National and provincial age standardized mortality rate in Iran (per 100,000) for both sexes and the percentage of change (Δ).

In 2019, hepatitis C had the highest death rate among the different main etiologies of liver diseases globally, responsible for approximately 4.8 deaths per 100,000 population. Alcohol followed, with a death rate of 4.5 deaths per 100,000 population. This statistic shows the age-standardized death rates associated with chronic liver disease/cirrhosis in 2019 worldwide, by etiology.

This statistic displays the number of alcoholic liver disease related deaths in Scotland in 2021, by gender and age. The number of deaths from alcoholic liver disease was higher among men than women. In 2021, 87 men and 55 women aged between 55 and 59 years old died from alcoholic liver disease.